Puma Biotechnology (NASDAQ:PBYI – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.
A number of other equities research analysts also recently weighed in on the company. TD Cowen upped their target price on Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday, August 7th. Weiss Ratings cut Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, November 10th. Two investment analysts have rated the stock with a Hold rating. According to data from MarketBeat, Puma Biotechnology has an average rating of “Hold” and an average price target of $6.00.
Get Our Latest Stock Analysis on Puma Biotechnology
Puma Biotechnology Stock Performance
Shares of NASDAQ:PBYI opened at $7.77 on Friday. The company has a 50 day moving average of $9.75 and a 200-day moving average of $8.02. The firm has a market cap of $401.71 million, a P/E ratio of 16.89 and a beta of 1.40. Puma Biotechnology has a twelve month low of $4.76 and a twelve month high of $11.50.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. Puma Biotechnology had a net margin of 10.26% and a return on equity of 17.50%. The business had revenue of $55.06 million during the quarter, compared to analysts’ expectations of $57.50 million. Equities research analysts forecast that Puma Biotechnology will post 0.37 EPS for the current year.
Insiders Place Their Bets
In other news, Director Troy Wilson sold 5,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $9.10, for a total transaction of $45,500.00. Following the completion of the transaction, the director owned 54,750 shares in the company, valued at approximately $498,225. This trade represents a 8.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandra Cesano sold 62,150 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $9.12, for a total transaction of $566,808.00. Following the transaction, the director owned 56,700 shares of the company’s stock, valued at approximately $517,104. This trade represents a 52.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 82,150 shares of company stock worth $733,808. 22.20% of the stock is owned by corporate insiders.
Institutional Trading of Puma Biotechnology
A number of hedge funds and other institutional investors have recently made changes to their positions in PBYI. BlackRock Inc. bought a new position in shares of Puma Biotechnology in the second quarter valued at $30,856,000. Globeflex Capital L P acquired a new stake in shares of Puma Biotechnology during the 2nd quarter valued at $3,105,000. Wellington Management Group LLP acquired a new stake in shares of Puma Biotechnology during the 2nd quarter valued at $1,023,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Puma Biotechnology during the 2nd quarter valued at $5,214,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Puma Biotechnology during the 2nd quarter valued at $2,926,000. 61.29% of the stock is currently owned by institutional investors.
About Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing medicines for cancer treatment. Its work centers on targeted therapies, particularly treatments for breast cancer. The company’s principal product is Nerlynx (neratinib), an oral HER2-targeted medicine. In the United States, it is approved for certain patients with early-stage HER2-positive breast cancer following trastuzumab-based treatment, and for some patients with advanced or metastatic HER2-positive breast cancer in combination with capecitabine.
Further Reading
- Five stocks we like better than Puma Biotechnology
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
